Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$32.12
+2.0%
$34.81
$29.25
$170.47
$12.42B1.866.68 million shs6.19 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.26
-1.8%
$8.19
$3.81
$23.86
$1.17B2.927.98 million shs2.60 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.05
-0.6%
$26.12
$24.48
$31.54
$142.08B0.6136.82 million shs51.26 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-7.00%-5.52%-7.14%-22.14%-70.69%
Novavax, Inc. stock logo
NVAX
Novavax
-2.25%-6.57%-0.27%-12.75%+56.90%
Pfizer Inc. stock logo
PFE
Pfizer
-1.44%-3.76%-5.54%-5.15%-8.69%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.1947 of 5 stars
4.01.00.04.61.92.50.6
Novavax, Inc. stock logo
NVAX
Novavax
3.8082 of 5 stars
3.22.00.04.71.61.70.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9874 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0083.69% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$18.00147.93% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9227.43% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/28/2025
Novavax, Inc. stock logo
NVAX
Novavax
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
2/27/2025
Novavax, Inc. stock logo
NVAX
Novavax
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.88N/AN/A$28.33 per share1.13
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.71N/AN/A($6.04) per share-1.20
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.23$3.93 per share6.38$15.81 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$1.33N/A90.752.85-32.18%N/A-17.05%5/9/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.778.270.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest NVAX, PFE, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2025Q4 24
Novavax, Inc. stock logo
NVAX
Novavax
-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.87%+2.50%121.99%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990160.84 million158.58 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer: Value Play or Past Its Prime?
WSJ report of probe to have limited impact on Pfizer, says Citi
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Trading Down 0.2% - What's Next?
U.S. prosecutors look into claim Pfizer delayed vaccine news, WSJ says
Why Pfizer Is My Largest Healthcare Position

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna stock logo

Moderna NASDAQ:MRNA

$32.12 +0.64 (+2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$32.12 +0.01 (+0.02%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.26 -0.13 (-1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$7.30 +0.04 (+0.55%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$25.05 -0.16 (-0.63%)
Closing price 03:59 PM Eastern
Extended Trading
$25.05 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.